AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Vistusertib (Primary) ; Everolimus
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms ZEBRA
- 25 May 2015 According to results presents at 2015 Genitourinary Cancers Symposium, this study was stopped early (May 2014) at this point efficacy data for PFS favoured everolimus (n=40).
- 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.